Dividend Aristocrats In Focus Part 19 Of 54: CR Bard (BCR)
Article By:
SureDividend
Read
Wednesday, October 15, 2014 9:09 AM EDT
In part 19 of my 54 part series on Dividend Aristocrats, I take a closer look at the future growth prospects and competitive advantage of medical products company CR Bard.
In this article: BCR
German Economy Appears Fragile: 3 Stocks To Dump Now
Article By:
Zacks Investment Research
Read
Tuesday, October 14, 2014 5:21 PM EDT
With leading economic indicators appearing bleak, the outcome bodes ill for the broader 18-country Eurozone and Germany in particular.
Alnylam Keeps Making New Strides In RNAi Research
Article By:
Terry Chrisomalis
Read
Tuesday, October 14, 2014 3:46 PM EDT
Alnylam posts positive phase 2 results in open-label study.
Dividend Aristocrats In Focus Part 18 Of 54: Becton, Dickinson & Company
Article By:
SureDividend
Read
Tuesday, October 14, 2014 10:48 AM EDT
This article covers the current events and future growth prospects of BDX. Learn more about BDX, one of the Top 10 stocks based on the 8 Rules of Dividend Investing.
Healthcare Review: PETX, PLX, CTIX, SMED, ALNY
Article By:
BioMedReports
Read
Tuesday, October 14, 2014 4:18 AM EDT
U.S. stocks slumped, with the Standard & Poor’s 500 Index falling below its 200-day average, as investors weighed prospects for Federal Reserve interest rate increases and slowing global economic growth.
Pall Corp.: Staying Bullish As The Company Hikes Its Dividend 11%
Article By:
Matt Schilling
Read
Friday, October 10, 2014 6:54 PM EDT
As Pall Corp. hikes its quarterly dividend by 11%, its trend behavior could reverse course and begin to move upward over the next several weeks.
In this article: PLL
Arrowhead Drops On Phase 2 Hepatitis B Results, Opportunity To Buy Shares
Article By:
Terry Chrisomalis
Read
Friday, October 10, 2014 10:04 AM EDT
Arrowhead Research Corp tumbles on Hepatitis B data
In this article: ARWR
Finally, Here Come The Banks: "Ebola Is A Tail-Risk That Can No Longer Be Ignored"
Article By:
Tyler Durden
Read
Wednesday, October 8, 2014 8:54 PM EDT
Those countries that best demonstrate their ability to avoid contagion, or best manage Ebola outbreaks when they occur, likely will see lower risk premia attached to their assets and higher equilibrium exchange rate values.
TransTech Digest: Age Evasion Or Compression Of Morbidity
Article By:
Patrick Cox
Read
Wednesday, October 8, 2014 6:26 PM EDT
Last week, an FDA committee voted 20 to 1 to make it more difficult for doctors to prescribe testosterone products. The committee also recommended that pharmaceutical companies be forced to perform additional safety testing.
Is Gilead Sciences Done Running?
Article By:
Nicholas Kitonyi
Read
Wednesday, October 8, 2014 7:56 AM EDT
Gilead Sciences seems to have slowed over the last six weeks after hitting a high of $110 on September 3. The stock had rallied from $65 per share to trade at $110 within a period of five months, but the current pullback has seen the price drop to about $104 per share. So is the rally over?
In this article: GILD
RXi Pharmaceuticals Posts Positive Phase 2a 3-Month Results In Hypertrophic Scars
Article By:
Terry Chrisomalis
Read
Tuesday, October 7, 2014 3:13 PM EDT
This validation is important because now the company is at a reduced risk investment level.
Healthcare Review: PTCT, HLF ALQA, ARIA, ADHD
Article By:
BioMedReports
Read
Monday, October 6, 2014 5:24 PM EDT
Global equity markets extended a rally on Monday that drew strength from a forecast-beating U.S. jobs report last week that bolstered confidence in the American economy and the Federal Reserve's monetary policy, but the dollar gave up some of its gains.
Reuters: Facebook Is Starting To Work On Healthcare Features
Article By:
Shelly Palmer
Read
Saturday, October 4, 2014 8:10 PM EDT
On the heels of fellow Silicon Valley technology companies Apple Inc (AAPL) and Google Inc (GOOG), Facebook is plotting its first steps into the fertile field of healthcare, said three people familiar with the matter.
In this article: FB